Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 42Carboplatin 38Cisplatin 34Paclitaxel 27Pemetrexed 23Gemcitabine 23Nivolumab 22Dexamethasone 17Ipilimumab 16Rituximab 15Fluorouracil 14Capecitabine 14Docetaxel 13trastuzumab deruxtecan 12durvalumab 12atezolizumab 12Cyclophosphamide 12Trastuzumab 11Lenalidomide 11olaparib 10130-nm albumin-bound paclitaxel 10Prednisone 9venetoclax 8daratumumab 8Oxaliplatin 8Cytarabine 8Bortezomib 8Bevacizumab 8zanubrutinib 7Vinorelbine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Has announcements × zenocutuzumab × Clear all
NCT02912949 2025-04-29

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Partner Therapeutics, Inc.

Phase 2 Active not recruiting
250 enrolled 2 FDA
GastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡